Jerry S. Wolinsky, M.D.

Bartels Family and Opal C. Rankin
Professor of Neurology

Director, MRI Analysis Center
Director, Multiple Sclerosis Research Group

Contact Information:

• Phone: 713-500-7135
  
• Fax: 713-500-7040
  

Board Certifications

• National Board of Medical Examiners - June 1970
• American Board of Psychiatry and Neurology - May 1975

Education and Training:

• Medical School: University of Illinois College of Medicine - 1969
• Residency: The University of California San Francisco, Neurology - 1973
• Fellowship: The University of California San Francisco, Experimental Neuropathology - 1975

Clinical Interests

• Multiple Sclerosis and Demyelinating Diseases of the CNS
• Quantitative Magnetic Resonance Imaging
• Clinical Trial Design

Research Interests / Current Trials

• Clayton Foundation for Research: Viral mimicry and multiple sclerosis
• Sanofi-Aventis: MRI Analysis Center for the teriflunomide studies in multiple sclerosis
• National Institutes of Health: Combination Therapy in Multiple Sclerosis
• National Institutes of Health: Automated MR Image Analysis in MS: Identification of a Surrogate

Biography

Jerry S. Wolinsky, M.D., is the Bartels Family Professor of Neurology and a member of the graduate faculty of the Graduate School of Biomedical Sciences at The University of Texas Health Science Center at Houston.

At UT, he directs the Multiple Sclerosis Research Group and the Magnetic Resonance Imaging Analysis Center. Dr. Wolinsky received his M.D. degree from The University of Illinois in 1969. Residency training in clinical neurology, a fellowship in experimental neuropathology and faculty appointment at The University of California San Francisco followed. While in San Francisco his research interests concentrated on the pathogenesis of viral infections of the nervous system, and his clinical efforts began to focus on experimental therapeutics of infections of the central nervous system and multiple sclerosis. He subsequently joined the faculty of The Johns Hopkins University Schools of Medicine, and Hygiene and Public Health in 1978 before settling in Houston in 1983. In Baltimore he applied more molecular tools to his basic investigations and became more interested in the primary and secondary immunopathogenesis of neural disease.

He is currently active in the design, implementation, conduct and analysis of clinical trials of multiple sclerosis and conducts basic and applied research in quantitative magnetic resonance imaging and magnetic resonance spectroscopic imaging in demyelinating diseases. He serves on review and advisory committees of the National Institutes of Health, the National Multiple Sclerosis Society, the Multiple Sclerosis International Federation, the Food and Drug Administration, numerous pharmaceutical houses and the recently established Sylvia Lawry Centre for Multiple Sclerosis Research. He is an Associate Editor of ACP Scientific American Medicine and on the editorial board of Multiple Sclerosis: Clinical and Laboratory Research.

He is recognized in The Best Doctors in America and America's Top Doctors. He has authored over 200 publications dealing with issues of relevance to neurovirology and neuroimmunology, clinical trials and the imaging of multiple sclerosis.

Publications and Medical/Scientific Participation

• Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D, PROMiSe Trial Study Group (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61:14-24.
• Schach S, Scholz M, Wolinsky JS, Kappos L (2007) Pooled historical MRI data as a basis for research in multiple sclerosis – A statistical evaluation. Multiple Sclerosis 13:509-16.
• Wolinsky JS (2007) The multiple sclerosis disease process as characterized by magnetic resonance imaging. In Multiple Sclerosis Therapeutics 3rd Edition, Cohen JA, Rudick RA, eds, Informa Healthcare, London, pp 45 - 63.
• Wolinsky JS (2006) The use of glatiramer acetate in the treatment of MS. In Advances in Neurology, volume 98, Multiple Sclerosis and Demyelinating Disease, Freedman M ed, Lippincott Williams & Wilkins, Philadelphia, pp 273 - 292.
• Filippi M, Rocca MA, Arnold DL, Bakshi R, Barkhof F, De Stefano N, Fazekas F, Frohman E, Wolinsky JS (2006) EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 13:313-25.
• Datta S, Sajja BR, He R, Wolinsky JS, Gupta RK, Narayana PA (2006) Segmentation and quantification of black holes in multiple sclerosis. NeuroImage 29:467-474.

Additional Information for Referring Physicians/Patients

• Clinical practice limited to multiple sclerosis, other demyelinating diseases and neurovirology